Showing results (1-10 of 46) with videos related to
Sort By:
Pageof 5
Medical Oncology (Northwood, London, England)|January 7, 2003
Gene-modified dendritic cells for immunotherapy against cancerAndreas Lundqvist, Pavel PisaCancer Immunology, Immunotherapy : CII|December 20, 2005
Tumor escape mechanisms in prostate cancerAshley M Miller, Pavel PisaInternational Immunopharmacology|August 19, 2014
All trans-retinoic acid abrogates the pro-tumorigenic phenotype of prostate cancer tumor-associated macrophagesPanagiotis Tsagozis, Martin Augsten, Pavel PisaExpert Review of Anticancer Therapy|October 18, 2008
Bevacizumab: direct anti-VEGF therapy in renal cell carcinomaBernard Escudier, Jan Cosaert, Pavel PisaMedical Oncology (Northwood, London, England)|September 18, 2007
Current perspectives in the treatment of advanced prostate cancerVictor Valdespino, Panagiotis Tsagozis, Pavel PisaCancer Immunology, Immunotherapy : CII|February 26, 2008
Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophagesPanagiotis Tsagozis, Fredrik Eriksson, Pavel PisaExpert Review of Vaccines|July 20, 2005
Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigensMaxim Pavlenko, Christoph Leder, Pavel PisaMethods in Molecular Biology (Clifton, N.J.)|March 29, 2008
DNA vaccination for prostate cancerAnna-Karin Roos, Alan King, Pavel PisaCancer Immunology, Immunotherapy : CII|April 10, 2002
Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X(L)Andreas Lundqvist, Takako Nagata, Rolf Kiessling, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005
Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancerAshley M Miller, Volkan Ozenci, Rolf Kiessling, et al.Pageof 5